In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 30, No. 15_suppl ( 2012-05-20), p. e13046-e13046
Abstract:
e13046 Background: To develop cancer vaccine, we investigated immune responses of the patients (pts) with metastatic breast cancer (MBC) with triple negative (TN) types to personalized peptide vaccine (PPV). Methods: Thirty-four pts including 8 TN-MBC were enrolled a phase II study of PPV. A maximum of four HLA-class IA (A2, A3s, A24, A26)-matched peptides showing higher antigen-specific IgG responses were administered. Levels of IgG reactive to each of the 31 peptides in the pre- and post-treatment plasma at every 6 times of vaccination were measured using LUMNEX system. Peptide-specific CTL responses were examined by INF-g ELISPOT. Results: All 34 pts had significant pre-existing humoral immunity, whereas only 13 of 31 patients, including 3 of 6 TN cases, showed pre-existing cellular immunity. Thirty-one of 34 pts, including 6 TN cases, achieved more than one cycle (6 times) of vaccination. The augmentation of the IgG responses specific to at least one of the vaccinated peptides was observed in 18 of 31 pts, including 3 of 6 TN cases. CTL responses were augmented in 16 of 31 pts, including 5 of 6 TN cases. IgG responses were boosted to greater levels with 12th vaccination in all 31 pts tested including 6 TN cases. Best clinical responses of 6 TN cases were 1 CR, 0 PR, 5 SD, and 0 PD, while those of the other 25 cases were 1 CR, 1 PR, 17 SD, and 6 PD, respectively. Conclusions: There were no significant differences between TN cases and the other cases of MBC with regard to immunological humoral and/or cellular responses to PPV.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/jco.2012.30.15_suppl.e13046
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2012
detail.hit.zdb_id:
2005181-5
Permalink